EIKN insider trading
HealthcareEikon Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Company website: eikontx.com
EIKN insider activity at a glance
FilingIQ tracks 38 insider transactions for EIKN in filings since Feb 6, 2026. The most recent transaction is dated Sep 3, 2026.
Across the full history, 10 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest EIKN Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for EIKN?
- FilingIQ tracks 38 Form 4 insider transactions for EIKN (Eikon Therapeutics, Inc.), covering filings from Feb 6, 2026 onwards. 1 of those are dated within the last 90 days.
- Are EIKN insiders net buyers or net sellers?
- Across the full Form 4 history for EIKN, 10 transactions (26%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EIKN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is EIKN in?
- Eikon Therapeutics, Inc. (EIKN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $825.69M.
Methodology & sources
Every EIKN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.